Martina Böhm-Weigert: Supporting Precision Dosing in Hemophilia with Fitusiran
Martina Böhm-Weigert, Scientific Support at Siemens Healthineers, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in RPTH, adding:
“QFITLIA (fitusiran) helps restore hemostasis by lowering antithrombin in individuals with hemophilia A or B, with or without inhibitors.
Maintaining the right therapeutic window is critical.
A recent study published in rpth shows that the INNOVANCE Antithrombin assay can accurately quantify antithrombin activity within the 15 to 35% range required for fitusiran dosing.
With strong precision and no interference from common hemophilia therapies, these data support confident clinical decision making in hemophilia A and B management.”
Title: Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points
Authors: Christoph Freidel, Martina Boehm-Weigert, Christine Dahler, Marek Demissie, Hong Wang, Mingjie Liu, Shariq Ali, Ekta Seth Chhabra
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI